In brief
The U.S. Department of Defense has launched a program that will require all active‑duty and reserve members age 30 or older to undergo a blood test for testosterone deficiency as part of their Periodic Health Assessment. Those with low hormone levels will be offered voluntary replacement therapy aimed at improving strength, stamina, and overall well‑being. Critics caution that while low levels can be managed, hormone therapy may lead to infertility and cardiovascular risk, and the policy has sparked debate over whether it should extend to women or be framed as a medical necessity rather than enhancement. The move highlights the military’s focus on preventative health measures and reflects broader trends in regulating hormone use in the U.S. armed forces.
US Defense Secretary Pete Hegseth today announced a new health‑screening program that will require all U.S. soldiers 30 years of age or older to test for testosterone deficiency during their Annual Health Assessment.
In a video posted on X, Hegseth noted that the initiative aims “to make sure you have the right testosterone levels to operate at your absolute best.” Personnel who test below the normal threshold will have access to voluntary hormone‑replacement therapy, a treatment that can restore muscle mass, energy and mood.
Pentagon spokesperson Sean Parnell confirmed that the testing is mandatory for every active‑duty and reserve member 30 or older and offered the option for younger soldiers who wish to be screened. “We owe our warriors the absolute best medical care in the world,” he said, stressing that a healthy testosterone baseline is part of sustaining a capable fighting force in the 21st‑century wars.
Military policy explicitly states that testosterone should not be used for non‑medical muscle enhancement. “Taking testosterone for non‑medical reasons is strictly prohibited,” Hegseth warned.
The decision has met with mixed reactions. Senator Tammy Duckworth urged that women also receive similar testing, noting that many female soldiers experience declining hormone levels and may benefit from tailored therapeutic options during perimenopause. In contrast, Congressman Chrissy Houlahan dismissed the policy as a “culture‑war obsession,” urging the Department to keep focus on real battlefield fitness.
Medical experts caution that hormone replacement is not a cure‑all. U.S. Food and Drug Administration (FDA) advisory panel chair Dr. Mohit Khera highlighted that while testosterone therapy can increase lean muscle and reduce depression, it may also reduce fertility in reproductive years and elevate cardiovascular risk. He urged careful assessment of symptoms before treatment.
Hegseth’s announcement comes amid a broader push by U.S. Health Secretary Robert F. Kennedy Jr. to streamline prescribing rules for testosterone, including loosening labeling restrictions and expanding practitioner access.
Experts predict the program will improve health outcomes for many soldiers, but it underscores ongoing debates around medical optimization versus natural enhancement in military contexts.
